Date: Tuesday, June 9, 2026
Time: 12:00 p.m. – 1:00 p.m. EDT
Location: Virtual Event
Facilitator: Carol Hill, Chair of Patient Representative Advisory Sub-Committee
Session #1
Trial #1: (BCC) CHRONO-RCC – Time-of-day–dependent administration of dual immune check point inhibitors (ICI) in advanced kidney cancer (NCT07338981)
Trial #2: (BCC) CHRONO-EVP – Time-of-day dependent administration of enfortumab vedotin and pembrolizumab (EV/P) in advanced bladder cancer (NCT07346053)
Speaker: Dr. Guliz Ozgun, MD, Clinical Assistant Professor of Medicine, Division of Medical Oncology, University of British Columbia, and Medical Oncologist, BC Cancer Vancouver
Session #2
ACCT Impact—AI-enabled Tracking of Practice Changes Arising from Portfolio Trials
Speaker: Rebecca Xu, 3CTN Portfolio and Informatics Manager
Reference: https://www.mdpi.com/2072-6694/17/24/4009
For more information and to register, please click HERE or email: info@3ctn.ca
Questions can be submitted through SLIDO HERE (event code: #TRIAL).